158 related articles for article (PubMed ID: 16150576)
1. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia.
Molina V; Reig S; Sanz J; Palomo T; Benito C; Sánchez J; Sarramea F; Pascau J; Desco M
Schizophr Res; 2005 Dec; 80(1):61-71. PubMed ID: 16150576
[TBL] [Abstract][Full Text] [Related]
2. Extensive gray matter volume reduction in treatment-resistant schizophrenia.
Anderson VM; Goldstein ME; Kydd RR; Russell BR
Int J Neuropsychopharmacol; 2015 Feb; 18(7):pyv016. PubMed ID: 25716781
[TBL] [Abstract][Full Text] [Related]
3. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.
Molina V; Taboada D; Aragüés M; Hernández JA; Sanz-Fuentenebro J
Schizophr Res; 2014 Sep; 158(1-3):223-9. PubMed ID: 25088730
[TBL] [Abstract][Full Text] [Related]
4. LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.
Tislerova B; Brunovsky M; Horacek J; Novak T; Kopecek M; Mohr P; Krajca V
Neuropsychobiology; 2008; 58(1):1-10. PubMed ID: 18781085
[TBL] [Abstract][Full Text] [Related]
5. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia.
Boonstra G; van Haren NE; Schnack HG; Cahn W; Burger H; Boersma M; de Kroon B; Grobbee DE; Hulshoff Pol HE; Kahn RS
J Clin Psychopharmacol; 2011 Apr; 31(2):146-53. PubMed ID: 21346618
[TBL] [Abstract][Full Text] [Related]
6. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.
van Haren NE; Hulshoff Pol HE; Schnack HG; Cahn W; Mandl RC; Collins DL; Evans AC; Kahn RS
Neuropsychopharmacology; 2007 Oct; 32(10):2057-66. PubMed ID: 17327887
[TBL] [Abstract][Full Text] [Related]
7. N-acetylaspartate (NAA) levels in selected areas of the brain in patients with chronic schizophrenia treated with typical and atypical neuroleptics: a proton magnetic resonance spectroscopy (1H MRS) study.
Szulc A; Galińska B; Tarasów E; Kubas B; Dzienis W; Konarzewska B; Poplawska R; Tomczak AA; Czernikiewicz A; Walecki J
Med Sci Monit; 2007 May; 13 Suppl 1():17-22. PubMed ID: 17507880
[TBL] [Abstract][Full Text] [Related]
8. Effects of alcohol consumption and antipsychotic medication on brain morphology in schizophrenia.
Nesvåg R; Frigessi A; Jönsson EG; Agartz I
Schizophr Res; 2007 Feb; 90(1-3):52-61. PubMed ID: 17218084
[TBL] [Abstract][Full Text] [Related]
9. Absence of regional brain volume change in schizophrenia associated with short-term atypical antipsychotic treatment.
McClure RK; Carew K; Greeter S; Maushauer E; Steen G; Weinberger DR
Schizophr Res; 2008 Jan; 98(1-3):29-39. PubMed ID: 17976957
[TBL] [Abstract][Full Text] [Related]
10. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients.
Molina V; Tamayo P; Montes C; De Luxán A; Martin C; Rivas N; Sancho C; Domínguez-Gil A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):948-54. PubMed ID: 18262704
[TBL] [Abstract][Full Text] [Related]
11. Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses.
Gogtay N; Sporn A; Clasen LS; Nugent TF; Greenstein D; Nicolson R; Giedd JN; Lenane M; Gochman P; Evans A; Rapoport JL
Arch Gen Psychiatry; 2004 Jan; 61(1):17-22. PubMed ID: 14706940
[TBL] [Abstract][Full Text] [Related]
12. Effect of clozapine on white matter integrity in patients with schizophrenia: a diffusion tensor imaging study.
Ozcelik-Eroglu E; Ertugrul A; Oguz KK; Has AC; Karahan S; Yazici MK
Psychiatry Res; 2014 Sep; 223(3):226-35. PubMed ID: 25012780
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year.
Sanz-Fuentenebro J; Taboada D; Palomo T; Aragües M; Ovejero S; Del Alamo C; Molina V
Schizophr Res; 2013 Sep; 149(1-3):156-61. PubMed ID: 23870807
[TBL] [Abstract][Full Text] [Related]
14. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study.
Machielsen MW; Veltman DJ; van den Brink W; de Haan L
J Psychopharmacol; 2014 Jul; 28(7):633-42. PubMed ID: 24646809
[TBL] [Abstract][Full Text] [Related]
15. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
Bondolfi G; Dufour H; Patris M; May JP; Billeter U; Eap CB; Baumann P
Am J Psychiatry; 1998 Apr; 155(4):499-504. PubMed ID: 9545995
[TBL] [Abstract][Full Text] [Related]
16. Cerebral atrophy and white matter disruption in chronic schizophrenia.
Andreone N; Tansella M; Cerini R; Rambaldelli G; Versace A; Marrella G; Perlini C; Dusi N; Pelizza L; Balestrieri M; Barbui C; Nosè M; Gasparini A; Brambilla P
Eur Arch Psychiatry Clin Neurosci; 2007 Feb; 257(1):3-11. PubMed ID: 16960652
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies.
Vita A; De Peri L; Deste G; Barlati S; Sacchetti E
Biol Psychiatry; 2015 Sep; 78(6):403-12. PubMed ID: 25802081
[TBL] [Abstract][Full Text] [Related]
18. Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment.
Ahmed M; Cannon DM; Scanlon C; Holleran L; Schmidt H; McFarland J; Langan C; McCarthy P; Barker GJ; Hallahan B; McDonald C
Neuropsychopharmacology; 2015 Sep; 40(10):2409-17. PubMed ID: 25829144
[TBL] [Abstract][Full Text] [Related]
19. Progressive brain changes in children and adolescents with first-episode psychosis.
Arango C; Rapado-Castro M; Reig S; Castro-Fornieles J; González-Pinto A; Otero S; Baeza I; Moreno C; Graell M; Janssen J; Parellada M; Moreno D; Bargalló N; Desco M
Arch Gen Psychiatry; 2012 Jan; 69(1):16-26. PubMed ID: 22213785
[TBL] [Abstract][Full Text] [Related]
20. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients.
Molina V; Sanz J; Sarramea F; Benito C; Palomo T
Psychiatry Res; 2004 May; 131(1):45-56. PubMed ID: 15246454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
